LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

Search

Simulations Plus Inc

Atvērts

SektorsVeselības aprūpe

16.94 -2.36

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

16.91

Max

17.43

Galvenie mērījumi

By Trading Economics

Ienākumi

-70M

-67M

Pārdošana

-2.1M

20M

P/E

Sektora vidējais

48.528

105.69

Dividenžu ienesīgums

0.48

Peļņas marža

-330.585

Darbinieki

243

EBITDA

327K

5.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-7.67% downside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.37%

Nākamie ieņēmumi

2025. g. 1. dec.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-5.6M

346M

Iepriekšējā atvēršanas cena

19.3

Iepriekšējā slēgšanas cena

16.94

Ziņu noskaņojums

By Acuity

50%

50%

182 / 374 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 12. nov. 21:55 UTC

Peļņas

Xero Beats 1st Half Profit Expectations Despite Melio Margin Hit

2025. g. 12. nov. 21:34 UTC

Peļņas

Cisco Systems Boosts Fiscal Year Outlook as 1Q Profit, Revenue Rise

2025. g. 12. nov. 23:44 UTC

Tirgus saruna

Nikkei May Trade in Range Amid Caution Over U.S. Econ -- Market Talk

2025. g. 12. nov. 23:38 UTC

Tirgus saruna

Gold Steady Ahead of Expected End to U.S. Government Shutdown -- Market Talk

2025. g. 12. nov. 23:13 UTC

Peļņas

Samsung Fire & Marine Insurance 3Q Net Profit Largely Met FactSet-Compiled Consensus

2025. g. 12. nov. 23:13 UTC

Peļņas

Samsung Fire & Marine Insurance 3Q Net KRW538.50B Vs. Net KRW554.56B >000810.SE

2025. g. 12. nov. 23:13 UTC

Peļņas

Samsung Fire & Marine Insurance 3Q Oper Pft KRW664.06B Vs. Pft KRW717.46B >000810.SE

2025. g. 12. nov. 23:13 UTC

Peļņas

Samsung Fire & Marine Insurance 3Q Rev KRW5.732T Vs. KRW5.326T >000810.SE

2025. g. 12. nov. 22:30 UTC

Tirgus saruna
Peļņas

Firefly Aerospace Sets Plan for Next Launch After Explosion -- Market Talk

2025. g. 12. nov. 22:18 UTC

Peļņas

Cisco Systems Boosts Outlook on AI-Driven Demand -- Update

2025. g. 12. nov. 22:12 UTC

Tirgus saruna

Bank of Canada Rate Hikes Could Start in 2H 2026 -- Market Talk

2025. g. 12. nov. 22:05 UTC

Peļņas

Pan American Silver: Campbell Succeeded Steve Busby >PAAS

2025. g. 12. nov. 22:04 UTC

Peļņas

Pan American Silver Named Scott Campbell as Operating Chief on Oct. 20

2025. g. 12. nov. 22:04 UTC

Peļņas

Pan American Silver 3Q Adj EPS 48c >PAAS

2025. g. 12. nov. 22:04 UTC

Peļņas

Pan American Silver 3Q Rev $884.4M >PAAS

2025. g. 12. nov. 22:04 UTC

Peļņas

Pan American Silver 3Q EPS 45c >PAAS

2025. g. 12. nov. 22:03 UTC

Peļņas

Manulife Financial: 3Q Book Value Per Common Shr C$26.07 >MFC.T

2025. g. 12. nov. 22:02 UTC

Peļņas

Manulife Financial 3Q Net C$1.8B >MFC

2025. g. 12. nov. 22:02 UTC

Peļņas

Manulife Financial 3Q Adj EPS C$1.16 >MFC

2025. g. 12. nov. 22:02 UTC

Peļņas

Manulife Financial 3Q EPS C$1.02 >MFC

2025. g. 12. nov. 21:53 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope Steel: Sale Strengthens Focus on Own Growth Investments

2025. g. 12. nov. 21:53 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope Steel Says Deal Subject to Indian Regulatory Approvals

2025. g. 12. nov. 21:53 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope Steel Estimates Net Profit After Tax on Sale of A$70 Million

2025. g. 12. nov. 21:53 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope Steel Expects Net Proceeds After Taxes, Fees of A$179 Million in 2H FY26

2025. g. 12. nov. 21:52 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope Steel: Tata BlueScope Steel JV a Provider of Coated, Painted Steel Products in India

2025. g. 12. nov. 21:51 UTC

Iegādes, apvienošanās, pārņemšana

BlueScope Steel Agrees to Sell 50% Stake in Tata BlueScope Steel Joint Venture to Tata Steel

2025. g. 12. nov. 21:50 UTC

Tirgus saruna
Peļņas

Basic Materials Roundup: Market Talk

2025. g. 12. nov. 21:49 UTC

Peļņas

Cisco Stock Climbs as Earnings Beat Expectations Amid Strong AI Demand -- Barrons.com

2025. g. 12. nov. 21:48 UTC

Peļņas

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares. -- Barrons.com

2025. g. 12. nov. 21:40 UTC

Peļņas

Xero Beats 1H Profit Expectations Despite Melio Margin Hit

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

-7.67% uz leju

Prognoze 12 mēnešiem

Vidējais 16 USD  -7.67%

Augstākais 16 USD

Zemākais 16 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

182 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat